Upon Breakthrough designation and Accelerated Approval, TLT will want to move to higher exchange. This will require more than just a share price raise. TLT will need to raise more capital to meet other criterias even if not expanding past NMBC, NSCLC, GBM and COVID-19. So those that think there won't be other raises of capital in the future lack understanding on the mechanisms and what the markets require. The good news is that this would lead us to more visibility, so more valuation.
Oncology has the highest R&D costs in any medecine fields. By having chosen its first indication wisely, TLT has been able to minimize the R&D costs to minimum in many ways that whiners silence intentionally, take for granted or dare to compare against
An indication that would have required a phase 3 would have required an average of 1B$ investment more. And PDT/PDC is also known to cost less than current big pharmas treatment models (go check the cost of Keytruda just for fun) abd can be used standalone, contrary to competition, thanks to higher efficacy % and less side effects.
And the rights acquired in 2010 from our TLD1433
- now target NMIBC,
- is also part of Rutherrin formula (NSCLC, GBM) when mixed with transferrin and
- has also demonstrated proof-of-concept in the destruction of enveloped viruses such as SARS-COV-2, Zika, influenza, MonkeyPox, herpes simplex, etc ....
And we have some whiners here that talk about "dilution". Pretty pathetic, don't you think?